Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury

Regulatory Peptides

Volumn 179, Issue 1-3, 2012, Pages 10-14

  Bauer, Sabrina ^a   Eisinger, Kristina ^a   Wiest, Reiner ^a   Karrasch, Thomas ^a   Scherer, Marcus N ^a   Farkas, Stefan ^a   Aslanidis, Charalampos ^a   Buechler, Christa ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

CHILD PUGH stage; CTGF; Hepatic vein; TIPS

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UREA;

ADOLESCENT; ADULT; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BLEEDING; BLOOD SAMPLING; CHILD PUGH SCORE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; LIVER VEIN; MALE; MELD SCORE; PLEURA EFFUSION; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SUPERIOR CAVA VEIN; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UREA BLOOD LEVEL; VARICOSIS; VARIX BLEEDING; VENOUS BLOOD; VENOUS PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; CASE-CONTROL STUDIES; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; HEPATIC VEINS; HEPATOCYTES; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PORTAL VEIN; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1;

BACTERIA (MICROORGANISMS);

EID: 84866306296     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.08.007     Document Type: Article

References (32)

1. Laleman W., Landeghem L., Wilmer A., Fevery J., Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005, 25:1079-1090.
2. Pinzani M., Rosselli M., Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol 2011, 25:281-290.
3. Gressner O.A., Gressner A.M. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008, 28:1065-1079.
4. Dendooven A., Gerritsen K.G., Nguyen T.Q., Kok R.J., Goldschmeding R. Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 2011, 16:289-301.
5. Gressner O.A., Lahme B., Demirci I., Gressner A.M., Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007, 47:699-710.
6. Abou-Shady M., Friess H., Zimmermann A., di Mola F.F., Guo X.Z., Baer H.U., Buchler M.W. Connective tissue growth factor in human liver cirrhosis. Liver 2000, 20:296-304.
7. Hora C., Negro F., Leandro G., Oneta C.M., Rubbia-Brandt L., Muellhaupt B., Helbling B., Malinverni R., Gonvers J.J., Dufour J.F. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int 2008, 28:370-376.
8. Williams E.J., Gaca M.D., Brigstock D.R., Arthur M.J., Benyon R.C. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000, 32:754-761.
9. Roestenberg P., van Nieuwenhoven F.A., Wieten L., Boer P., Diekman T., Tiller A.M., Wiersinga W.M., Oliver N., Usinger W., Weitz S., Schlingemann R.O., Goldschmeding R. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004, 27:1164-1170.
10. Tamatani T., Kobayashi H., Tezuka K., Sakamoto S., Suzuki K., Nakanishi T., Takigawa M., Miyano T. Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Biochem Biophys Res Commun 1998, 251:748-752.
11. Zhang D., Wang N.Y., Yang C.B., Fang G.X., Liu W., Wen J., Luo C. The clinical value of serum connective tissue growth factor in the assessment of liver fibrosis. Dig Dis Sci 2010, 55:767-774.
12. Guo-Qiu W., Nai-Feng L., Xiao-Bo V., Linxian L., Chen Z., Lixia G., Zhao L. The level of connective tissue growth factor in sera of patients with hepatitis B virus strongly correlates with stage of hepatic fibrosis. Viral Immunol 2010, 23:71-78.
13. Piao R.L., Brigstock D.R., Zhu J., Zhang M.L., Gao R.P. Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis. World J Gastroenterol 2012, 18:2280-2286.
14. Gressner A.M., Yagmur E., Lahme B., Gressner O., Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem 2006, 52:1815-1817.
15. Kovalenko E., Tacke F., Gressner O.A., Zimmermann H.W., Lahme B., Janetzko A., Wiederholt T., Berg T., Muller T., Trautwein C., Gressner A.M., Weiskirchen R. Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat 2009, 16:612-620.
16. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25:223-229.
17. Moller S., Henriksen J.H., Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int 2008, 2:416-428.
18. Garcia-Pagan J.C., Caca K., Bureau C., Laleman W., Appenrodt B., Luca A., Abraldes J.G., Nevens F., Vinel J.P., Mossner J., Bosch J. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010, 362:2370-2379.
19. Rossle M., Haag K., Ochs A., Sellinger M., Noldge G., Perarnau J.M., Berger E., Blum U., Gabelmann A., Hauenstein K., et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994, 330:165-171.
20. Wanninger J., Weigert J., Wiest R., Bauer S., Karrasch T., Farkas S., Scherer M.N., Walter R., Weiss T.S., Hellerbrand C., Neumeier M., Schaffler A., Buechler C. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine 2011, 55:435-440.
21. Wanninger J., Wiest R., Bauer S., Neumeier M., Eisinger K., Farkas S., Scherer M.N., Schaffler A., Buechler C. Portal levels of latent transforming growth factor-beta are related to liver function in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2011, 23:218-223.
22. Weigert J., Neumeier M., Wanninger J., Bauer S., Farkas S., Scherer M.N., Schnitzbauer A., Schaffler A., Aslanidis C., Scholmerich J., Buechler C. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010, 95:1404-1411.
23. Weigert J., Neumeier M., Wanninger J., Filarsky M., Bauer S., Wiest R., Farkas S., Scherer M.N., Schaffler A., Aslanidis C., Scholmerich J., Buechler C. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010, 72:342-348.
24. Wiest R., Weigert J., Wanninger J., Neumeier M., Bauer S., Schmidhofer S., Farkas S., Scherer M.N., Schaffler A., Scholmerich J., Buechler C. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Cytokine 2011, 53:178-183.
25. Durand F., Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008, 28:110-122.
26. Wadhawan M., Dubey S., Sharma B.C., Sarin S.K. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status. Dig Dis Sci 2006, 51:2264-2269.
27. Rossle M., Gerbes A.L. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010, 59:988-1000.
28. Gressner O.A., Peredniene I., Gressner A.M. Connective tissue growth factor reacts as an IL-6/STAT3-regulated hepatic negative acute phase protein. World J Gastroenterol 2011, 17:151-163.
29. Walter R., Wanninger J., Bauer S., Eisinger K., Neumeier M., Weiss T.S., Amann T., Hellerbrand C., Schaffler A., Scholmerich J., Buechler C. Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis. Exp Mol Pathol 2011, 91:740-744.
30. Weng H.L., Liu Y., Chen J.L., Huang T., Xu L.J., Godoy P., Hu J.H., Zhou C., Stickel F., Marx A., Bohle R.M., Zimmer V., Lammert F., Mueller S., Gigou M., Samuel D., Mertens P.R., Singer M.V., Seitz H.K., Dooley S. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 2009, 50:230-243.
31. Olde Damink S.W., Jalan R., Dejong C.H. Interorgan ammonia trafficking in liver disease. Metab Brain Dis 2009, 24:169-181.
32. Lotterer E., Wengert A., Fleig W.E. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology 1999, 29:632-639.